We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Cell-based functional and potency assays provide the critical bridge between molecular binding events and therapeutic biological activity, capturing the integrated cellular response to biologics, small molecules, and cellular therapies in physiologically relevant contexts. Unlike biochemical assays that measure isolated molecular interactions, cell-based assays report on receptor signaling, pathway activation, proliferation induction, and targeted cell killing—functional endpoints that directly predict clinical efficacy and safety. These assays are indispensable for biologics potency determination, biosimilar comparability assessment, and mechanism-of-action validation throughout drug discovery and development. Profacgen offers a comprehensive Cell-Based Functional & Potency Assays platform integrating reporter gene, signaling, proliferation, and cytotoxicity detection systems to deliver quantitative, mechanism-informed data that supports regulatory submission and therapeutic optimization.
Introduction to Cell-Based Potency Assays
Potency is the quantitative measure of a therapeutic's biological activity, expressed relative to a qualified reference standard. For biologics—including monoclonal antibodies, recombinant proteins, vaccines, and cell therapies—potency must be demonstrated using cell-based assays that reflect the product's specific mechanism of action, as required by ICH Q6B and FDA biosimilar guidance.
Cell-based potency assays differ from animal-based potency tests by offering:
Mechanism Specificity: Direct measurement of the molecular pathway mediating therapeutic effect (e.g., STAT phosphorylation for interferons, NF-κB suppression for TNF inhibitors, ADCC for antibodies)
Human Relevance: Human cell lines or primary cells expressing the target receptor in native conformation and signaling context
Precision and Reproducibility: Controlled conditions with statistical process control, enabling lot-to-lot consistency monitoring and stability indication
Reduced Animal Use: Replacement, reduction, and refinement (3Rs) alignment with ethical and regulatory trends away from in vivo bioassays
Luciferase-based reporters coupled to pathway-specific promoters (NF-κB, STAT, CREB, TCF/LEF) provide amplified, sensitive readouts of transcription factor activity. Ideal for cytokine potency, GPCR ligand characterization, and pathway-biased drug assessment.
Detection: Firefly and Renilla luciferase–based luminescence systems; luminescence microplate readers.
Direct quantification of post-translational modifications and second messenger dynamics by TR-FRET, AlphaLISA, flow cytometry, and live-cell imaging. Captures proximal pathway activation with sub-minute temporal resolution.
Quantification of mitogenic activity and growth inhibition through metabolic activity, DNA synthesis, or biomass measurement. Core platform for growth factor potency and cytostatic/cytotoxic drug profiling.
Mechanism-resolved measurement of cell death through membrane integrity loss, caspase activation, and metabolic collapse. Essential for ADC, CAR-T, bispecific antibody, and oncolytic virus potency.
Integrated Multi-Platform Coverage: Reporter gene, signaling, proliferation, and cytotoxicity assays within a single provider, enabling cross-validation and mechanism-informed platform selection
Regulatory-Compliant Potency: GLP-aligned assay validation, reference standard qualification, and statistical equivalence testing supporting IND, BLA, and biosimilar submissions
Primary Cell and Immuno-Oncology Expertise: Validated human PBMC, T cell, NK cell, and patient-derived assays for immune effector function and cell therapy potency
3D and Advanced Models: Tumor spheroid, organoid, and co-culture formats capturing stromal interactions, penetration limitations, and hypoxic gradients
High-Throughput Execution: 384- and 1536-well automated screening with integrated data pipelines for large compound and biologic panels
Mechanistic Interpretation: Expert correlation of functional data with binding kinetics, signaling pathways, and clinical outcomes to generate predictive hypotheses
Representative Case Studies
Case 1: Integrated Potency Panel for an Anti-PD-1 Biosimilar
Background:
A biosimilar developer required comprehensive functional comparability data for an anti–PD-1 antibody using a clinically established reference product. Regulatory expectations include demonstration of equivalent mechanism-of-action across the full spectrum of PD-1 biological activities, including blockade of PD-L1 binding, restoration of T cell activation, and enhancement of cytokine production.
Our Solution:
Profacgen designed a three-tier potency panel: (1) Binding—SPR for PD-1 affinity and FcγR binding; (2) Signaling—NFAT-luciferase reporter in Jurkat-PD-1 cells with PD-L1-expressing APCs; and (3) Functional—primary human T cell proliferation (CFSE dilution) and IFN-γ secretion (ELISA) with allogeneic MLR stimulation. Biosimilar and innovator were tested head-to-head across all tiers.
Final Results:
All three tiers demonstrated equivalence: SPR KD within 5%, NFAT reporter EC50 within 8%, and T cell proliferation/IFN-γ within 12%. The integrated panel provided mechanistic depth beyond binding alone, demonstrating that the biosimilar recapitulated the complete PD-1 functional signature. The data supported successful regulatory approval with the T cell functional assay incorporated into QC lot release.
Case 2: Reporter Gene and Cytotoxicity Multiplex for a CAR-T Product
Background:
A CAR-T developer needed a potency assay for a CD19-directed product that captured both target recognition and killing efficacy, with rapid turnaround for patient-specific release testing. Standard 51Cr release assays were too slow and hazardous for clinical manufacturing support.
Our Solution:
Profacgen established a multiplex platform: (1) NFAT-luciferase reporter in CD19⁺ target cells to quantify CAR-mediated signaling activation upon co-culture; (2) ATP-based cell viability assay on remaining target cells to assess cytotoxicity; and (3) LDH release for membrane damage confirmation. The assay was completed in 24 hours versus 4 days for 51Cr, with E:T ratio optimization (1:1 to 10:1) and serial killing assessment by target cell replenishment.
Final Results:
The multiplex assay achieved a Z'-factor of 0.78 with CV < 10%. NFAT activation correlated with cytotoxicity (R² = 0.92), enabling either readout as release criteria. The 24-hour turnaround supported clinical manufacturing schedules, and the non-radioactive format eliminated regulatory radiation safety requirements. The assay was validated per ICH Q2(R1) and transferred to the client's QC laboratory.
Q: Why are cell-based assays required for biologics potency instead of biochemical binding?
A: Biochemical binding measures molecular affinity but cannot predict functional consequences. Biologics often require Fc effector function, receptor clustering, or conformational change for activity—features only captured in cellular contexts. Regulatory agencies mandate cell-based potency assays that reflect the product's specific mechanism of action. Binding assays serve as complementary identity tests but cannot substitute for functional potency.
Q: How do you ensure lot-to-lot consistency in cell-based potency assays?
A: Consistency is maintained through: (1) qualified cell banks with low passage number (< 15) and regular STR authentication; (2) reference standard tracking with historical control charts; (3) assay performance metrics (Z'-factor, EC50 of positive control, signal-to-background) with acceptance criteria; (4) qualified FBS and medium lots reserved for assay duration; (5) analyst training and qualification; and (6) inter-laboratory comparison for multi-site programs. Profacgen implements statistical process control with Shewhart charts to detect drift before it impacts study validity.
Q: What is relative potency, and how is it calculated?
A: Relative potency is the activity of a test sample expressed as a percentage of a qualified reference standard under identical assay conditions. It is calculated by parallel-line analysis of log-dose response curves (4-parameter logistic) or direct EC50 ratio comparison. Equivalence is assessed by two-one-sided test (TOST) with 90% confidence intervals against predefined margins (typically 80–125% for biosimilars). Profacgen reports relative potency with full statistical documentation including parallelism confirmation and confidence interval determination.
Q: Can cell-based potency assays replace animal testing?
A: Cell-based assays increasingly replace animal potency tests per the 3Rs principle (replacement, reduction, refinement). Regulatory agencies accept validated cell-based assays for: EPO (TF-1 proliferation), G-CSF (NFS-60 proliferation), IFN (antiviral or reporter), and numerous monoclonal antibodies. Complete replacement requires demonstration that the cell-based assay correlates with clinical efficacy and is more precise than the animal test. Profacgen supports assay replacement through validation packages including correlation studies, precision assessment, and regulatory consultation.
Q: How do you select the optimal potency assay platform for a new biologic?
A: Platform selection follows the mechanism-of-action: (1) receptor signaling biologics (cytokines, growth factors) → reporter gene or signaling assays; (2) mitogenic factors → proliferation assays; (3) cytotoxic antibodies (ADC, bispecifics) → cytotoxicity with mechanism resolution; (4) immune modulators → primary cell functional assays (T cell activation, cytokine release). Profacgen conducts feasibility studies with multiple platforms, selecting the assay with optimal dynamic range, precision, and regulatory precedent for the specific product class.
Q: What is the typical project timeline for cell-based potency assay development?
A: Standard timelines: 4–6 weeks for assay feasibility and platform selection; 6–8 weeks for optimization (cell density, treatment time, detection conditions); 8–10 weeks for pre-validation (precision, specificity, range); 10–14 weeks for full GLP validation with documented robustness and stability. Biosimilar comparability studies add 4–6 weeks for statistical equivalence analysis. Cell therapy potency assays with primary cells require 12–16 weeks for donor variability assessment and assay qualification.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
